Indeed, the increased expression of PD-L1 was also observed in epidermal growth factor receptor (EGFR)-resistant tumors, suggesting that the activation of the immune checkpoint may delay the treatment efficacy of TKIs in cancer patients [31]. The gene discussed is EGFR; the disease is cancer.